5:55 PM
 | 
Oct 02, 2007
 |  BC Extra  |  Clinical News

Lundbeck's Lu AA21004 meets Phase II endpoint

H. Lundbeck (CSE:LUN) said oral Lu AA21004 met the primary endpoint of a significantly improved score...

Read the full 68 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >